콘텐츠로 건너뛰기
Merck
  • Advanced glycation end products in human diabetic lens capsules.

Advanced glycation end products in human diabetic lens capsules.

Experimental eye research (2021-07-25)
Johanna Rankenberg, Stefan Rakete, Brandie D Wagner, Jennifer L Patnaik, Christian Henning, Anne Lynch, Marcus A Glomb, Ram H Nagaraj
초록

Advanced glycation end products (AGEs) accumulate with age in human lens capsules. AGEs in lens capsules potentiate the transforming growth factor beta-2-mediated mesenchymal transition of lens epithelial cells, which suggests that they play a role in posterior capsule opacification after cataract surgery. We measured AGEs by liquid chromatography-mass spectrometry in capsulorhexis specimens obtained during cataract surgery from nondiabetic and diabetic patients with and without established retinopathy. Our data showed that the levels of most AGEs (12 out of 13 measured) were unaltered in diabetic patients and diabetic patients with retinopathy compared to nondiabetic patients. There was one exception: glucosepane, which was significantly higher in diabetic patients, both with (6.85 pmol/μmol OH-proline) and without retinopathy (8.32 pmol/μmol OH-proline), than in nondiabetic patients (4.01 pmol/μmol OH-proline). Our study provides an explanation for the similar incidence of posterior capsule opacification between nondiabetic and diabetic cataract patients observed in several studies.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Leucine Aminopeptidase, microsomal from porcine kidney, Type IV-S, ammonium sulfate suspension, 10-40 units/mg protein (Bradford)
Sigma-Aldrich
Carboxypeptidase Y from baker′s yeast (S. cerevisiae), lyophilized powder, ≥50 units/mg protein